Mineralys Therapeutics' Lorundrostat NDA Accepted by FDA
Mineralys Therapeutics announced that the FDA has accepted the new drug application, or NDA, for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, target action date of December 22.
